Skip to main content
CDC Website

Centers for Disease Control and Prevention,National Center for HIV Viral Hepatitis STD and TB Prevention

ACT Against AIDS Leadership Inititative: Harnessing the Strength of African-American Organizations to Fight HIV and AIDS

This information sheet discusses the Act Against AIDS Leadership Initiative (AAALI), a $10 million, five-year partnership with 14 of the nation’s leading African-American organizations. The AAALI aims to use the collective strength and reach of these traditional, longstanding African-American institutions to increase HIV awareness, knowledge, and action in black communities. The information sheet describes how the organizations were chosen and the work they are expected to undertake such as communication, mobilization, and outreach activities.

TB Elimination: Tuberculin Skin Testing

This information sheet discusses TB testing using the Mantoux tuberculin skin test (TST) to determine whether an individual is infected with Mycobacterium TB. It discusses how the TST is administered, how it is read, how TST reactions are interpreted the classification of the TST skin test reaction, what are false-positive and false-negative reactions, who can receive a TST and how often the test can be repeated, what is a boosted reaction, why two-step testing is conducted, and whether TSTs can be given to persons receiving vaccinations.

TB Elimination: Targeted Tuberculosis Testing and Interpreting Tuberculin Skin Test Results

The information sheet discusses targeted TB testing, the decision to focus on groups at highest risk for latent TB infection (LTBI) and advises appropriate treatment and treatment completion to prevent LTBI progressing to active disease. It explains tuberculin skin testing (TST) and the test reactions that indicate whether an individual has LTBI; lists the criteria for classifying positive TST reactions; and describes persons at risk for developing TB disease including clinical conditions that increase the risk of LTBI becoming TB disease.

Effective HIV and STD Prevention Programs for Youth: A Summary of Scientific Evidence

This information sheet discusses the importance of bringing HIV and STD prevention programs into schools so adolescents can make healthy choices. It also provides information on CDC's Division of Adolescent and School Health (DASH). Topics include: Effective HIV/STD Prevention Education Programs; Youth Asset-Development Programs; CDC's Ongoing Efforts to Identify and Implement Effective HIV/STD Prevention Programs for Youth.

Bringing High-Quality HIV and STD Prevention to Youth in Schools: CDC's Division of Adolescent and School Health

This information sheet discusses the importance of bringing HIV and STD prevention programs into schools so adolescents can make healthy choices. It also provides information on CDC's Division of Adolescent and School Health (DASH). Topics include: schools play a critical role in HIV and STD prevention; prevention programs can reduce risk behaviors; DASH promotes effective prevention through schools; National HIV/AIDS Strategy; and Dash's programs are data driven and evidence based.

The Role of STD Prevention and Treatment in HIV Prevention

This information sheet discusses the link between STDs and HIV. It explains how individuals with STDS have an increased susceptibility to HIV and individuals with HIV have increased infectiousness. The information sheet discusses how STD treatment can slow the spread of HIV and the implications for HIV and STD prevention programs. Information is provided for accessing the services of national health organizations.

Testing for Tuberculosis (TB)

In a question and answer format, this information sheet discusses testing for tuberculosis (TB). There are two kinds of tests that are used to determine if a person has been infected with TB bacteria: the tuberculin skin test (TST) and TB blood tests.

Targeted Tuberculin Testing and Interpreting Tuberculin Skin Results

This information sheet discusses targeted tuberculin testing focusing on the groups at highest risk for latent TB infection (LTBI). It advises that testing should be given to those at highest risk for developing TB, and once TB disease has been ruled out, then it should be offered to those who would benefit from LTBI treatment. It also explains the steps that should be taken to ensure completion of the regimen.

Interferon-Gamma Release Assays (IGRAs) - Blood Tests for TB Infection

This information sheet discusses interferon-gamma release assays (IGRAs), which are whole-blood tests used in diagnosing both latent TB infection and TB disease. It notes that two IGRAs have been approved by the US Food and Drug Administration (FDA) and are commercially available in the United States. The information sheet explains how the IGRAs work; the advantages, disadvantages, and limitations of IGRAs; steps in administering these tests; interpretation; recommendations on when to use them; and whether IGRAs can be given to persons receiving vaccinations.

[Hepatitis A Vaccine: What You Need to Know]

This information sheet discusses the hepatitis A vaccine. It explains hepatitis A virus infection, its effect on the liver, and its transmission and symptoms, and advises that a vaccine can prevent the disease. The information sheet lists who should get the vaccine and when, who should not get the vaccine or should wait, whether there are any risks or adverse reactions to the vaccine, different types of reactions, and what to do. It describes the National Vaccine Injury Compensation Program and provides sources of further information.
Was this page helpful? Give Feedback